BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Bojkova D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler JD, Pfeiffer A, Wagner JUG, Shumliakivska M, Dimmeler S, Olmer R, Martin U, Vondran FWR, Toptan T, Rothweiler F, Zehner R, Rabenau HF, Osman KL, Pullan ST, Carroll MW, Stack R, Ciesek S, Wass MN, Michaelis M, Cinatl J Jr. Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. iScience 2023;26:105944. [PMID: 36644320 DOI: 10.1016/j.isci.2023.105944] [Reference Citation Analysis]
2 Cheng W, Xu T, Cui L, Xue Z, Liu J, Yang R, Qin S, Guo Y. Discovery of Amphiphilic Xanthohumol Derivatives as Membrane-Targeting Antimicrobials against Methicillin-Resistant Staphylococcus aureus. J Med Chem 2023;66:962-75. [PMID: 36584344 DOI: 10.1021/acs.jmedchem.2c01793] [Reference Citation Analysis]
3 Simonetti L, Nilsson J, McInerney G, Ivarsson Y, Davey NE. SLiM-binding pockets: an attractive target for broad-spectrum antivirals. Trends Biochem Sci 2023:S0968-0004(22)00332-2. [PMID: 36623987 DOI: 10.1016/j.tibs.2022.12.004] [Reference Citation Analysis]
4 Beltz LA. COVID-19. Pathogenic Coronaviruses of Humans and Animals 2023. [DOI: 10.1016/b978-0-323-98809-4.00013-9] [Reference Citation Analysis]
5 Garry RF. Lassa fever - the road ahead. Nat Rev Microbiol 2023;21:87-96. [PMID: 36097163 DOI: 10.1038/s41579-022-00789-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gidari A, Sabbatini S, Pallotto C, Bastianelli S, Pierucci S, Busti C, Schiaroli E, Francisci D. Nelfinavir: An Old Ally in the COVID-19 Fight? Microorganisms 2022;10. [PMID: 36557724 DOI: 10.3390/microorganisms10122471] [Reference Citation Analysis]
7 Askr H, Elgeldawi E, Aboul Ella H, Elshaier YAMM, Gomaa MM, Hassanien AE. Deep learning in drug discovery: an integrative review and future challenges. Artif Intell Rev 2022. [DOI: 10.1007/s10462-022-10306-1] [Reference Citation Analysis]
8 Shetnev AA, Volobueva AS, Panova VA, Zarubaev VV, Baykov SV. Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. Life 2022;12:1832. [DOI: 10.3390/life12111832] [Reference Citation Analysis]
9 Ravindran V, Wagoner J, Athanasiadis P, Den Hartigh AB, Sidorova JM, Ianevski A, Fink SL, Frigessi A, White J, Polyak SJ, Aittokallio T. Discovery of host-directed modulators of virus infection by probing the SARS-CoV-2-host protein-protein interaction network. Brief Bioinform 2022;23. [PMID: 36305426 DOI: 10.1093/bib/bbac456] [Reference Citation Analysis]
10 Wagoner J, Herring S, Hsiang TY, Ianevski A, Biering SB, Xu S, Hoffmann M, Pöhlmann S, Gale M Jr, Aittokallio T, Schiffer JT, White JM, Polyak SJ. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr 2022;10:e0333122. [PMID: 36190406 DOI: 10.1128/spectrum.03331-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Blasiak A, Truong ATL, Wang P, Hooi L, Chye H, Tan SB, You K, Remus A, Allen DM, Chai LYA, Chan CEZ, Lye DCB, Tan GG, Seah SGK, Chow EK, Ho D. IDentif.AI-Omicron: Harnessing an AI-Derived and Disease-Agnostic Platform to Pinpoint Combinatorial Therapies for Clinically Actionable Anti-SARS-CoV-2 Intervention. ACS Nano 2022;16:15141-54. [PMID: 35977379 DOI: 10.1021/acsnano.2c06366] [Reference Citation Analysis]
12 Madariaga-Mazón A, Naveja JJ, Becerra A, Alberto Campillo-Balderas J, Hernández-Morales R, Jácome R, Lazcano A, Martinez-Mayorga K. Subtle structural differences of nucleotide analogs may impact SARS-CoV-2 RNA-dependent RNA polymerase and exoribonuclease activity. Comput Struct Biotechnol J 2022;20:5181-92. [PMID: 36097553 DOI: 10.1016/j.csbj.2022.08.056] [Reference Citation Analysis]
13 Lam HYI, Guan JS, Mu Y. In Silico Repurposed Drugs against Monkeypox Virus. Molecules 2022;27:5277. [DOI: 10.3390/molecules27165277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Dhawan M, Saied AA, Mitra S, Alhumaydhi FA, Emran TB, Wilairatana P. Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2? Biomed Pharmacother 2022;154:113522. [PMID: 36030585 DOI: 10.1016/j.biopha.2022.113522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Bojkova D, Stack R, Rothenburger T, Kandler JD, Ciesek S, Wass MN, Michaelis M, Cinatl J. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants.. [DOI: 10.1101/2022.07.22.501169] [Reference Citation Analysis]
16 Gidari A, Sabbatini S, Schiaroli E, Bastianelli S, Pierucci S, Busti C, Comez L, Libera V, Macchiarulo A, Paciaroni A, Vicenti I, Zazzi M, Francisci D. The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro. Microorganisms 2022;10:1475. [DOI: 10.3390/microorganisms10071475] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Lam HYI, Guan JS, Mu Y. In silico repurposed drugs against monkeypox virus.. [DOI: 10.1101/2022.07.17.500371] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Bojkova D, Reus P, Panosch L, Bechtel M, Rothenburger T, Kandler J, Pfeiffer A, Wagner JU, Shumliakivska M, Dimmeler S, Olmer R, Martin U, Vondran F, Toptan T, Rothweiler F, Zehner R, Rabenau H, Osman KL, Pullan ST, Carroll M, Stack R, Ciesek S, Wass MN, Michaelis M, Cinatl J. Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform.. [DOI: 10.1101/2022.07.17.500346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bojkova D, Stack R, Rothenburger T, Kandler JD, Ciesek S, Wass MN, Michaelis M, Cinatl J. Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants. Journal of Infection 2022. [DOI: 10.1016/j.jinf.2022.07.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Lin Q, Lu C, Hong Y, Li R, Chen J, Chen W, Chen J. Animal models for studying coronavirus infections and developing antiviral agents and vaccines. Antiviral Res 2022;203:105345. [PMID: 35605699 DOI: 10.1016/j.antiviral.2022.105345] [Reference Citation Analysis]
21 Ianevski A, Giri AK, Aittokallio T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res 2022:gkac382. [PMID: 35580060 DOI: 10.1093/nar/gkac382] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
22 Ianevski A, Yao R, Simonsen RM, Myhre V, Ravlo E, Kaynova GD, Zusinaite E, White JM, Polyak SJ, Oksenych V, Windisch MP, Pan Q, Lastauskienė E, Vitkauskienė A, Matukevičius A, Tenson T, Bjørås M, Kainov DE. Mono- and combinational drug therapies for global viral pandemic preparedness. iScience 2022;25:104112. [DOI: 10.1016/j.isci.2022.104112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
23 Aittokallio T. What are the current challenges for machine learning in drug discovery and repurposing? Expert Opin Drug Discov 2022;:1-3. [PMID: 35255749 DOI: 10.1080/17460441.2022.2050694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Oksenych V, Kainov DE. Broad-Spectrum Antivirals and Antiviral Drug Combinations. Viruses 2022;14:301. [DOI: 10.3390/v14020301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. [DOI: 10.1038/s41422-022-00618-w] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 76.0] [Reference Citation Analysis]
26 Ianevski A, Yao R, Simonsen RM, Myhre V, Ravlo E, Kaynova GD, Zusinaite E, White JM, Polyak SJ, Oksenych V, Windisch MP, Pan Q, Lastauskienė E, Vitkauskienė A, Matukevičius A, Tenson T, Bjørås M, Kainov DE. Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness.. [DOI: 10.1101/2022.01.15.476444] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Athanasiadis P, Ianevski A, Skånland SS, Aittokallio T. Computational Pipeline for Rational Drug Combination Screening in Patient-Derived Cells. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2095-3_14] [Reference Citation Analysis]
28 Ianevski A, Ahmad S, Anunnitipat K, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE. Seven classes of antiviral agents. Cell Mol Life Sci 2022;79:605. [PMID: 36436108 DOI: 10.1007/s00018-022-04635-1] [Reference Citation Analysis]